BioSpace News Archive

Biotech Bay

Ashvattha Therapeutics Announces Two Oral Presentations at the World Molecular Imaging Congress 2021

Scientific collaborators at Stanford University will present preclinical data for novel neuro-imaging agent, 18 F-OP-801, for Alzheimer’s Disease and other neurodegenerative diseases marked by neuroinflammation

September 29, 2021
·
4 min read
Drug Development

Topline Results from Shionogi Phase 2 Study in Japan Show Akili’s Digital Treatment Was Well-received and Improved Inattention Symptoms in Children with ADHD

Akili Interactive (“Akili”), a leading cognitive medicine company improving health through game-changing technologies, today announced topline results of a Phase 2 study of SDT-001 (Japanese version of AKL-T01), a digital therapeutic designed to improve measures of attention in children diagnosed with attention-deficit/hyperactivity disorder (ADHD).

September 29, 2021
·
9 min read
Drug Development

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp Subpopulation analysis

SCYNEXIS, Inc. today announced an oral presentation of analyses of interim data from its ongoing Phase 3 FURI study showing favorable clinical activity of oral ibrexafungerp in severe hospital-based fungal infections across multiple serious fungal infections.

September 29, 2021
·
6 min read
Business

Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021

Theratechnologies Inc. announced today that it will report financial results for its third quarter of fiscal 2021 ended August 31, 2021 on Wednesday, October 13, 2021.

September 29, 2021
·
1 min read
Drug Development

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults

The Janssen Pharmaceutical Companies today announced the initiation of its Phase 3 EVERGREEN study.

September 29, 2021
·
7 min read
Business

Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy.

September 29, 2021
·
5 min read